AJANTPHARM vs WANBURY: Stock Comparison

Ajanta Pharma Limited vs Wanbury Ltd

Live data: 28 July 2026, 4:08 PM IST • Source: NSE and company filings

Ajanta Pharma Limited is the larger company by market capitalisation. Ajanta Pharma Limited shows a higher dividend yield, faster revenue growth and lower leverage, while Wanbury Ltd shows a lower P/E, a higher ROE and a higher ROCE. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Ajanta Pharma Limited and Wanbury Ltd on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, AJANTPHARM is more favourable on 7 of 13 scored metrics and WANBURY on 6These counts are context-free and are not an overall rating.

Key Differences

Market Cap
AJANTPHARM is the larger company
₹41,751 Cr vs ₹1,091 Cr
P/E Ratio
WANBURY has a lower P/E
0x vs 39.47x
P/B Ratio
WANBURY has a lower P/B
0x vs 9.21x
EPS
AJANTPHARM has higher earnings per share
₹84.57 vs ₹13.1
Dividend Yield
AJANTPHARM has a higher dividend yield
1.66% vs 0%
Revenue Growth (TTM YoY)
AJANTPHARM has faster revenue growth
21.5% vs -19.2%
EPS Growth (TTM YoY)
AJANTPHARM has faster EPS growth
18.6% vs 0%
Qtr Sales Growth
WANBURY has stronger quarterly sales growth
24.5% vs 21.5%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricAJANTPHARMWANBURY
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricAJANTPHARMWANBURY
Live Price₹3,342.4₹312.45
Day Change-1.29%-5.1%
Volume76,5972.85 L
52-Week High₹3,598.8₹358.85
52-Week Low₹2,329.9₹161.5
Distance from 52W High-7.12%-12.93%

Valuation

MetricAJANTPHARMWANBURY
Market Cap₹41,751 Cr₹1,091 Cr
P/E Ratio39.47x0x
P/B Ratio9.21x0x
EPS₹84.57₹13.1
Book Value₹362.41₹18.1
Dividend Yield1.66%0%

Growth

MetricAJANTPHARMWANBURY
Revenue Growth (TTM YoY)21.5%-19.2%
EPS Growth (TTM YoY)18.6%0%
Qtr Sales Growth21.5%24.5%
Qtr Profit Growth18.4%1,197%

Profitability & Leverage

MetricAJANTPHARMWANBURY
ROE27.1%76.5%
ROCE34.5%36.6%
Net Margin19.38%10.17%
Operating Margin27.5%14%
Debt to Equity0.06x3.02x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricAJANTPHARMWANBURY
Promoter Holding63.48% 2.77 pp34.36%
FII Holding7.68% 0.58 pp0.89% 0.3 pp
DII Holding21.8% 3.43 pp0.06% 0.06 pp
Public Holding7.03% 0.09 pp56.03% 0.36 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Ajanta Pharma Limited and Wanbury Ltd.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.